Astrocytes

The Glial Consortium and the Collapse of Clearance: A Systems-Level Analysis of Autophagic Failure in Neurodegeneration

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

---

Abstract

For decades, the pathogenesis of neurodegenerative diseases has been dominated by a rigidly neuron-centric paradigm. This traditional model posits that cell-autonomous failures in proteostasis and the subsequent accumulation of toxic protein aggregates inevitably lead to neuronal apoptosis, thereby driving the clinical manifestations of cognitive and motor decline. This thesis systematically dismantles that isolated framework, advancing instead a highly integrated, systems-level, glia-centric model of neurodegeneration. By exhaustively examining the macroautophagic, microautophagic, and chaperone-mediated autophagic machinery across the diverse cellular populations of the central nervous system (CNS), this research identifies glial cells—specifically astrocytes—not merely as passive scaffolding or secondary responders to injury, but as the primary vanguard of transcellular proteostasis. The investigation exhaustively details the complex molecular mechanisms of astrocytic autophagy, including the groundbreaking and paradigm-shifting phenomenon of transmitophagy, whereby astrocytes actively engulf and enzymatically degrade damaged neuronal mitochondria to prevent the extracellular release of toxic mitochondrial DNA.

Furthermore, this thesis delineates the distinct, highly specialized autophagic vulnerabilities of other crucial CNS cell types and subcellular structures. It explores microglial phagocytic exhaustion, the transition to the senescence-associated secretory phenotype (SASP), and the resultant chronic neuroinflammation that exacerbates dopaminergic and cortical neuron loss. It also examines oligodendroglial macroautophagy in the context of myelin basic protein turnover, demonstrating that senescent oligodendrocyte precursor cells drive cognitive decline independently of demyelination. Finally, the analysis shifts to highly vulnerable subcellular domains, detailing the unique geographical challenges of presynaptic autophagy and the selective degradation of the endoplasmic reticulum (ER-phagy) via specialized, subdomain-specific receptors such as FAM134B, SEC62, and ATL3. Ultimately, this research argues that neurodegeneration is fundamentally a systemic collapse of the glial-neuronal autophagic network. This comprehensive paradigm shift necessitates a radical reorientation of future therapeutic interventions, moving away from isolated neuronal rescue toward the complex restoration of glial metabolic homeostasis, transcellular clearance pathways, and network-wide proteostatic resilience.

Introduction

The mammalian central nervous system operates under unparalleled metabolic and proteostatic demands, consuming a disproportionate share of the organism's energetic resources to maintain continuous electrical signaling and synaptic plasticity.¹ Within this highly demanding environment, post-mitotic neurons—which generally do not undergo cell division to dilute accumulated cellular damage—are burdened with complex, highly polarized morphologies, extending axons that can traverse vast physical distances relative to the size of the cell soma.³ These unique architectural and physiological characteristics render neurons exquisitely sensitive to oxidative stress, the accumulation of misfolded proteins, and the presence of damaged, ROS-producing organelles.³ Historically, the dominant etiological models of devastating neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic Lateral Sclerosis (ALS), have been defined almost entirely by the presence of pathological intraand extracellular accumulations. The progressive buildup of amyloid-beta (Aβ) plaques, hyperphosphorylated neurofibrillary tau tangles, alpha-synuclein (α-syn) inclusions, and mutant huntingtin (mHTT) aggregates has traditionally focused the scientific gaze inward, exclusively on the neuron's internal failure to clear these specific pathogenic aggregates.² However, this restricted, cell-autonomous focus presents a profound theoretical and empirical inadequacy. The neuron-centric model fails comprehensively to explain the distinct spatial propagation of disease pathology, the highly specific regional vulnerability of certain neuronal circuits, or why robust inflammatory and metabolic transcriptomic signatures often precede overt neuronal loss by years or even decades.⁸ If neurons are the ultimate, visible casualties of these neurodegenerative diseases, the initiating failures and the fundamental collapse of homeostasis frequently occur within the surrounding, highly dynamic glial network.⁸ Glial cells, comprising astrocytes, microglia, and oligodendrocytes, constitute approximately half of all cells within the central nervous system, yet their active participation in the fundamental mechanisms of disease initiation has historically been marginalized.¹⁰ The primary research problem addressed in this doctoral thesis is the critical limitation of the cell-autonomous neuronal model in explaining the etiology and progression of neurodegenerative disease, specifically in the context of autophagic failure. Autophagy, an evolutionarily conserved lysosomal degradation pathway essential for cellular quality control, is universally impaired in late-onset neurodegenerative diseases.¹² Yet, the exact nature of this impairment is highly cell-type specific. This thesis investigates the pivotal role of astrocytes in autophagy failure, repositioning these abundant cells from supportive, homeostatic bystanders to central, active mediators of disease pathology and transcellular proteostasis.¹⁵ Furthermore, it interrogates the parallel autophagic vulnerabilities of microglia, oligodendrocytes, and specific, highly specialized subcellular structures—namely, the distal synaptic terminal and the complex reticular network of the endoplasmic reticulum (ER). The significance of this comprehensive inquiry lies in its potential to fundamentally redirect the trajectory of pharmacological development and therapeutic strategy. Decades of clinical trials targeting neuronal aggregates, such as Aβ, have repeatedly failed to yield disease-modifying therapies, suggesting a flaw in the underlying conceptual framework.⁶ By elucidating the cell-specific autophagic pathways and identifying their precise points of catastrophic failure across the glial consortium, this research provides a comprehensive, interconnected framework of neurodegeneration. The core hypothesis of this thesis is that neurodegeneration does not originate as a discrete neuronal event, but rather as a progressive, systemic collapse of the highly integrated glial-neuronal autophagic network, driven by age-related glial senescence and transcellular metabolic uncoupling. Recognizing this network collapse opens novel, highly targeted avenues for interventions, including senotherapeutics aimed at microglial exhaustion and pharmacological modulators designed to restore astrocytic autophagic plasticity.⁸

Literature Review and Historiographical Positioning

The conceptual and terminological evolution of autophagy in cellular neurobiology represents one of the most significant and transformative paradigm shifts in modern molecular pathology. To understand the current theoretical landscape, it is imperative to trace the historiography of autophagic research and its gradual intersection with neuropathology. The term "autophagy," derived from the Greek auto (self) and phagy (eating), was christened in 1963 by the Belgian biochemist Christian de Duve, shortly after his Nobel Prize-winning discovery of the lysosome.¹² Early electron microscopy studies by de Duve, alongside researchers such as Hruban and Spargo, observed what appeared to be the progressive sequestration and breakdown of cytoplasmic organelles within membrane-limited vacuoles, establishing the lysosome as the primary site of intracellular degradation.¹² However, for nearly three decades following this discovery, the field of autophagy languished. The process was largely viewed as a non-selective, bulk degradation response to severe cellular stress or nutrient starvation, and researchers struggled to identify the underlying molecular machinery.²⁰ The historiographical turning point—the initiation of the modern era of autophagy research—occurred in the early 1990s. Yoshinori Ohsumi and Michael Thumm independently identified and cloned the first autophagy-related genes (ATGs) using the budding yeast Saccharomyces cerevisiae as a model organism.¹⁸ Concurrently, Daniel J. Klionsky discovered the cytoplasm-to-vacuole targeting (CVT) pathway, revealing that autophagy could be a highly selective, tightly regulated process rather than merely a bulk starvation response.¹⁹ The discovery that these ATG homologs were highly conserved across all eukaryotes, including mammals, brought revolutionary changes to the field, shifting autophagy from a phenomenological observation to a rigorously definable molecular cascade.²⁰ In the early 2000s, seminal works began actively linking autophagic machinery to human disease pathogenesis. Beth Levine's groundbreaking identification of the BECLIN1 gene (the mammalian ortholog of yeast Atg6) as a putative tumor suppressor established the first definitive link between autophagy and cancer.¹⁸ In the realm of neurobiology, pioneering researchers such as Ralph Nixon and David Rubinsztein firmly established that the post-mitotic nature of neurons renders them critically, uniquely dependent on the continuous, basal activity of the endosomal-lysosomal pathway to clear aggregate-prone proteins.⁴ Nixon's seminal work demonstrated that endosomal-lysosomal defects are among the absolute earliest observable cellular abnormalities in Alzheimer's disease, physically manifesting before the widespread deposition of amyloid plaques.²¹ These foundational studies cemented the understanding that genetic mutations impairing autophagosome formation, lysosomal acidification, or cargo recognition are direct, causative factors in a wide spectrum of adult-onset neurodegenerative disorders.⁴ Despite these monumental advances in understanding the molecular mechanics of autophagy, the historiography of neurodegeneration remained staunchly and problematically "neuron-centric." Throughout the late 20th and early 21st centuries, glial cells were frequently overlooked, relegated to an undefined, passive supportive role in the background of the diseased brain.⁷ In the traditional disease models, glia were rarely viewed as the primary culprits responsible for the initiation of pathology; rather, they were seen as reactive surveillance cells that simply responded to the signals of dying neurons.⁸ The past decade, however, has witnessed a tectonic, theoretically disruptive shift toward a "glia-centric" or network-based framework of neurodegeneration.⁸ A major watershed moment in this historiographical shift was the 2014 publication by Nicholas Marsh-Armstrong and colleagues in the Proceedings of the National Academy of Sciences (PNAS). This landmark study documented the phenomenon of "transmitophagy" in the optic nerve head of mice, empirically shattering the long-standing biological dogma that a healthy cell must necessarily degrade its own organelles.²⁴ By demonstrating that retinal ganglion cells actively outsource the degradation of damaged axonal mitochondria to surrounding astrocytes, this work provided undeniable proof of profound transcellular autophagic interdependence.²⁴ Concurrently, the theoretical understanding of brain aging—the single greatest risk factor for neurodegeneration—has been radically reshaped by the concept of cellular senescence. The modern glia-centric framework posits that age-related functional remodeling, including impaired proteostasis and mitochondrial dysfunction, leads to the accumulation of senescent glial cells.⁸ These cells exhibit a Senescence-Associated Secretory Phenotype (SASP), releasing pro-inflammatory cytokines and matrix-remodeling enzymes that actively dismantle synaptic integrity and drive neurodegeneration long before overt neuronal apoptosis occurs.⁸ This thesis positions itself strategically at the vanguard of this new historiography. It synthesizes the formerly disparate literature on cell-specific macroautophagy, chaperone-mediated autophagy (CMA), and highly selective microautophagy (such as ER-phagy and mitophagy) to construct a comprehensive, holistic model of glial-neuronal interdependence, explicitly detailing the mechanisms and catastrophic consequences of its age-related collapse.

Research Design and Epistemological Framework

To rigorously address the complex, transcellular nature of autophagy failure in the brain, this thesis employs an advanced, integrative systems neurobiology approach, deeply grounded in molecular pathology and spatially resolved transcriptomics. Unlike traditional, reductionist methodologies that frequently isolate single cellular populations in vitro to study intrinsic biochemical cascades, the epistemological framework of this research insists on evaluating autophagic flux as a dynamic, deeply interconnected intercellular economy. The conceptual modeling fundamentally relies on defining the "metabolic coupling" that exists between distinct glial populations and neurons, viewing the CNS not as a collection of autonomous units, but as a singular, highly coordinated proteostatic syncytium.¹ The primary analytical lens adopted here categorizes autophagy not merely as a basal, homeostatic waste-disposal system, but as an active, highly responsive regulator of cellular phenotypic state, synaptic plasticity, and potent inflammatory signaling.² Evidence is meticulously synthesized from a broad spectrum of state-of-the-art sources. This includes diverse in vivo murine transgenic models designed to replicate specific human pathologies (e.g., APP/PS1 transgenic mice for Alzheimer's disease, and α-synuclein overexpressing TG mice for Parkinson's disease), which provide crucial insights into the systemic progression of autophagic failure.²⁷ Furthermore, the analysis relies heavily on complex ex vivo co-culture assays that permit the observation of direct physical and chemical interactions between varied cell types, such as the transfer of mitochondria or the secretion of toxic chemokines.²⁹ Finally, the framework incorporates advanced postmortem human brain tissue spatial transcriptomics, ensuring that the biochemical findings in murine models map accurately onto the clinical reality of human neurodegenerative pathology.⁸ By tracking the expression, lipidation, and specific spatial localization of highly conserved molecular markers—most notably LC3B (microtubule-associated protein 1A/1B-light chain 3), SQSTM1 (p62), and various specific selective autophagy receptors like FAM134B and ATL3—this research reconstructs the structural and functional breakdown of the CNS degradation machinery across varying temporal and pathological scales. The methodological strength of this thesis lies in its synthesis of these varied data streams, allowing for the construction of a robust, predictive model of how a single molecular failure in a specific glial sub-population can inevitably cascade into widespread neural network collapse.

Chapter 1: The Astrocytic Vanguard: Proteostasis,

Transmitophagy, and Synaptic Plasticity

Astrocytes are the most abundant and functionally diverse glial cells within the central nervous system. Historically conceptualized as mere structural "glue" holding the neuronal network together, they are now understood to serve as the absolute central regulators of the CNS microenvironment.² Their complex, highly ramified morphological role extends far beyond physical scaffolding; astrocytes actively coordinate neurotransmitter clearance, regulate precisely tuned extracellular ion homeostasis (particularly potassium buffering), maintain the strict integrity of the blood-brain barrier (BBB) via intricate interactions with vascular endothelial cells, and provide indispensable, continuous metabolic and neurotrophic support to highly demanding neuronal populations.² Within this incredibly complex context of transcellular management, astrocytic autophagy emerges as a critical, highly dynamic mediator of overall brain health, operating through several distinct but temporally overlapping mechanisms that protect the vulnerable neuronal soma and its extensive projections. 1.1 Autophagic Plasticity and Extracellular Amyloid Clearance In the classical pathogenesis of Alzheimer’s disease, the pathological accumulation of amyloid-beta (Aβ) oligomers and larger fibrillar plaques is recognized as a primary, initiating driver of subsequent synaptic failure, massive neuroinflammation, and eventual neuronal apoptosis.⁶ However, recent neurobiological literature fundamentally reframes the efficient clearance of these toxic, extracellular proteins not as an intrinsic neuronal capability, but heavily as an astrocyte-dependent autophagic process.² Astrocytic autophagy is not a static pathway; rather, it exhibits profound, highly responsive "plasticity" in the face of pathological, neurotoxic stimuli.¹⁷ When the brain parenchyma is exposed to elevated levels of Aβ, astrocytes detect this cellular stress and respond by transiently inducing the rapid expression of the LC3B gene, while simultaneously turning on a prolonged, sustained transcription of the SQSTM1 gene, which encodes the p62 cargo receptor.²⁷ These proteins are absolutely essential for the genesis of the autophagosome and the highly specific recognition and engulfment of ubiquitinated cargo, respectively. In vivo modeling using advanced genetic techniques powerfully demonstrates the critical nature of this dynamic astrocytic response. In APP/PS1 transgenic mice—a widely utilized, standard in vivo model that faithfully replicates amyloid pathology—the astrocyte-specific genetic knockdown of LC3B and SQSTM1 results in a dramatic, catastrophic exacerbation of Aβ plaque formation.²⁷ This autophagic blockade in astrocytes leads directly to increased reactive astrogliosis (quantitatively indicated by severe upregulation of GFAP positivity), extensive mitochondrial dysfunction within the glia, and a rapid, precipitous decline in both measurable neuronal markers and functional cognitive performance.²⁷ Conversely, the targeted, experimental overexpression of LC3B specifically within the astrocytic population significantly reduces the overall burden of Aβ aggregates in the brains of these APP/PS1 mice, actively rescuing cognitive function.¹⁷ This robust data paradigm unequivocally indicates that Aβ-induced astrocytic autophagic plasticity is not merely a reactionary, selfish survival mechanism employed by the astrocyte to protect its own internal homeostasis. Rather, it acts as a dedicated, highly evolved transcellular sink designed specifically to clear the extracellular milieu, accelerate the degradation of polyamines and urea cycle intermediates, and physically protect the structural integrity of adjacent, highly vulnerable neurons.¹⁷ Consequently, when this specific astrocytic clearance capacity is genetically overwhelmed, pharmacologically inhibited, or naturally degraded due to age-related senescence, the resultant failure guarantees the unchecked, exponential propagation of Aβ pathology throughout the cortex.⁸ 1.2 The Paradigm Shift of Transmitophagy While the clearance of extracellular protein aggregates is vital, perhaps the most radical, biologically disruptive challenge to the traditional cell-autonomous model of neurodegeneration is the recent discovery and characterization of "transmitophagy." Neurons, particularly massive projection neurons such as retinal ganglion cells (RGCs) or upper motor neurons, possess extremely long, unmyelinated or partially myelinated axons that can extend vast physical distances from the cellular soma.³⁵ The intense bioenergetic demands required to maintain resting membrane potentials and drive action potentials along these lengthy axons require incredibly dense, localized populations of mitochondria.²⁵ Over time, these organelles undergo severe, irreversible damage from the continuous generation of reactive oxygen species (ROS) and localized metabolic stress.³⁵ Traditional cell biology dictated that these damaged mitochondria must undergo retrograde transport back to the neuronal soma to be degraded by somatic lysosomes—an extraordinarily slow, energetically costly, and inefficient process.³⁵ However, cutting-edge in vivo research reveals that healthy axons actively and deliberately evulse their damaged mitochondria, completely outsourcing their mitochondrial quality control to the surrounding glial architecture.²⁵ In regions such as the optic nerve head (ONH), unmyelinated RGC axons are observed forming large, morphologically distinct protrusions. These axonal protrusions contain dense, highly concentrated clusters of damaged mitochondria—averaging 29 ± 18 mitochondria per individual protrusion—alongside other trapped axoplasmic components like microtubules.²⁵ Crucially, these specific protrusions form almost exclusively at sites where the neuronal axon is in direct, physical contact with the fine processes of resident phagocytic astrocytes.²⁵ These protrusions are subsequently shed from the axon, becoming free-floating "evulsions," which are immediately and efficiently engulfed by the adjacent astrocytes.²⁵ Once internalized, the astrocytic endosomal-lysosomal system assumes the immense metabolic burden of fully degrading these exogenous organelles, facilitating the extensive enzymatic degradation of the neuronal mitochondrial DNA (mtDNA) within the acidic environment of the astrocytic lysosome.²⁵ Quantitative analyses, utilizing virally introduced tandem fluorophore protein reporters that specifically tag acidified mitochondria, reveal that this process is highly active under normal physiological conditions; the measurable "mitophagy index" is approximately 2.7-fold higher in the astrocyte-rich ONH than in the actual retinal ganglion cell soma.²⁵ The systemic failure of this delicate transmitophagy process has catastrophic, cascading consequences for both the neuron and the broader CNS tissue. If astrocytic lysosomal function declines—as is naturally observed with advancing age, or aggressively in specific genetic lysosomal storage disorders such as Multiple Sulfatase Deficiency (MSD)—the improperly degraded, highly immunogenic neuronal mtDNA can be released into the extracellular space.²⁵ This leakage acts as a potent Damage-Associated Molecular Pattern (DAMP), triggering severe, chronic neuroinflammatory responses from local microglia.⁸ Furthermore, the inability of the astrocyte network to efficiently clear neuronal mitochondria deprives the axon of necessary physical space, exacerbates localized oxidative stress, and severely impacts metabolic efficiency, ultimately driving the characteristic axonal degeneration that is clinically observed in the earliest, prodromal stages of various neurodegenerative diseases.²⁵ The profound importance of this glial capability is highlighted in mouse models of MSD caused by mutations in the Sulfatase Modifying Factor 1 (SUMF1) gene. Cre/Lox models demonstrate that an astrocyte-specific deletion of Sumf1 in vivo induces massive lysosomal storage and autophagic dysfunction exclusively within astrocytes.²⁹ Remarkably, this targeted astrocytic failure is entirely sufficient to induce the widespread, non-cell autonomous degeneration of otherwise perfectly healthy, wild-type cortical neurons, proving definitively that neurons cannot survive if their astrocytic autophagic support network collapses.²⁹ 1.3 Synaptic Pruning, Proteome Editing, and Network Excitability Beyond the bulk transcellular clearance of metabolic waste and damaged organelles, both astrocytic and neuronal autophagy are intimately, mechanistically tied to the highly precise, dynamic regulation of synaptic plasticity—specifically, the mechanisms underlying Long-Term Potentiation (LTP) and Long-Term Depression (LTD), which form the biological basis of learning and memory.¹⁴ Far from being a blunt instrument of degradation, autophagy actively "edits" the synaptic proteome in an activity-dependent manner, allowing neural circuits to structurally and functionally adapt to varied experiences.¹⁴ During the induction of LTD, where synaptic responsiveness to glutamate must be strategically weakened, local autophagic flux is rapidly upregulated to selectively sequester and degrade specific postsynaptic cargoes.¹⁴ This includes the targeted destruction of AMPA receptors (specifically the GluR1 subunits) and critical structural scaffolding proteins such as PSD-95.¹⁴ By systematically reducing the density of these receptors, autophagy directly reduces the electrical responsiveness of the postsynaptic membrane. When this highly localized autophagic system fails at the synapse, the physiological consequences for global network excitability are dire and immediate. A genetic or pathological deficiency in autophagic flux (such as the deletion of core Atg5 genes) leads invariably to the aberrant accumulation of various regulatory proteins, including the regulatory subunits (R1α/β) of protein kinase A (PKA), which are normally targeted to autophagosomes by the specific receptor AKAP11.¹⁴ This toxic accumulation actively suppresses local PKA activity, leading to widespread hypophosphorylation of downstream substrates within the Postsynaptic Density (PSD). The physical and morphological result of this biochemical failure is a massively enlarged PSD that is heavily overloaded with GluR1-containing AMPA receptors.¹⁴ This structural aberration forces the neuron into a state of hyper-responsiveness, driving the elevated neuronal network activity and startle-evoked seizures frequently observed in severe autophagic deficiency models.¹⁴ Astrocytes, which intricately enwrap these synapses to form the functional "tripartite synapse," are critical supporting actors in this highly localized arena. Their failure to efficiently clear the extracellular debris generated by neurotransmission, or their inability to properly modulate the delicate redox environment, directly and significantly impedes the localized autophagic capacity of the neuronal synaptic terminal, further linking glial failure to excitotoxic neuronal death.²

Chapter 2: The Glial Consortium: Microglia and Oligodendrocytes in Autophagic Failure

While astrocytes manage the massive tasks of broad metabolic support, BBB maintenance, and macroscopic waste clearance, the broader glial consortium—comprising the brain's resident immune cells (microglia) and its dedicated myelinating cells (oligodendrocytes)—possesses highly specialized, distinct autophagic functions. The progressive failure of these unique pathways dictates the specific, varied progression of neurodegenerative phenotypes seen across different clinical disease profiles. 2.1 Microglial Phagocytic Exhaustion and the SASP Microglia, representing the resident innate immune system of the CNS, are developmentally and functionally distinct from all other neuroglial cell types, originating entirely from early erythromyeloid progenitors in the embryonic yolk sac rather than the neuroectoderm.³⁹ As the primary, specialized phagocytes of the brain parenchyma, they perpetually survey their local microenvironment for invading pathogens, cellular debris, and aberrant protein formations. Under healthy, physiological conditions, microglia utilize a combination of selective macroautophagy, chaperone-mediated autophagy, and non-canonical, highly specialized pathways such as LC3-associated endocytosis (LANDO) and LC3-associated phagocytosis (LAP) to efficiently internalize and safely degrade massive quantities of extracellular aggregates, including toxic α-synuclein and Aβ oligomers.⁵ However, in the context of advancing chronological age and the onset of chronic neurodegenerative disease, the microglial autophagic and lysosomal machinery gradually and inevitably fails, leading to a catastrophic, irreversible phenotypic shift.⁸ When pattern recognition receptors (PRRs) on the microglial surface—such as Toll-like receptors (TLRs) and CD36—are chronically and relentlessly activated by an overwhelming, systemic burden of misfolded proteins, the microglial lysosomes become physically engorged, alkalinized, and functionally impotent.⁵ This profound failure in autophagic flux traps the microglial cell in a state of suspended degradation, initiating a vicious, self-reinforcing intracellular cycle of severe oxidative stress and subsequent mitochondrial dysfunction.⁵ The resulting systemic pathology is driven fundamentally by the transition of these cells into a Senescence-Associated Secretory Phenotype (SASP) and the subsequent, aggressive activation of the NLRP3 inflammasome complex.⁸ These hyperactivated, yet autophagic-deficient microglia undergo a morphological and transcriptomic transition from a neuroprotective, resolving (M2-like) state to a highly neurotoxic, chronically pro-inflammatory (M1-like) state. In this compromised phenotype, they secrete an unrelenting onslaught of potent pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1 beta (IL-1β), which act to create and maintain a chronic, low-level neurotoxic environment throughout the brain tissue.⁵ In the specific pathology of Parkinson's disease, this precise failure in microglial selective autophagy and the subsequent massive cytokine release is recognized as a primary, driving mechanism of the highly targeted, selective death of vulnerable dopaminergic neurons in the substantia nigra.⁵ Furthermore, specific molecular regulatory failures compound this disaster; for instance, the pathological overexpression of the regulatory factor Synaptotagmin-11 (Syt11) has been shown to actively inhibit both cytokine secretion and standard phagocytosis, essentially trapping the microglia in a state of paralyzed, inflammatory exhaustion where they can neither clear toxic debris nor signal effectively to recruit adaptive immune responses.⁵ 2.2 Oligodendroglial Autophagy and Myelin Integrity Oligodendrocytes, the myelinating cells of the CNS, are responsible for generating and meticulously maintaining the lipid-rich myelin sheaths that insulate long axonal projections, facilitating the rapid, efficient saltatory conduction of action potentials essential for all complex vertebrate behavior. The lifelong maintenance of this extensive myelin architecture is a massive, incredibly taxing metabolic undertaking that requires the continuous, precisely regulated synthesis and turnover of both complex lipids and structural proteins. Recent advanced biological studies clearly demonstrate that basal macroautophagy within the oligodendrocyte cellular lineage is absolutely, unequivocally essential for the continuous, healthy turnover of key structural components, particularly myelin basic protein (MBP).⁴³ When the autophagic machinery is genetically or pathologically inactivated in either immature oligodendrocyte precursor cells (OPCs) or fully mature, myelinating oligodendrocytes, the crucial turnover of MBP is profoundly and immediately impaired.⁴³ Consequently, undegraded MBP rapidly accumulates in the cellular cytoplasm as massive, toxic multimeric aggregates, severely failing to be properly and functionally incorporated into the integral structure of the myelin sheath.⁴³ This profound intracellular disruption translates directly into macroscopic pathology, leading to severe, detrimental changes in myelin sheath structure, causing widespread dysmyelination and contributing significantly to adult-onset, progressive demyelination phenotypes commonly associated with severe neurodegenerative decline and motor dysfunction.⁴³ Crucially, emerging scientific evidence highlights a profound, myelination-independent role of OPCs in the trajectory of general brain aging and cognitive health. Research demonstrates that standard autophagic flux naturally and precipitously declines in chronologically aged OPCs, a failure that results directly in the accumulation of senescent OPC populations scattered throughout the aging brain.⁴³ These senescent, autophagy-defective OPCs undergo their own distinct pathological transition, beginning to actively release harmful inflammatory signals and chemokines—such as CCL3 and CCL5—which signal via CCR5 pathways to directly impair neighboring glutamatergic transmission.⁴³ This toxic signaling drastically reduces overall neuronal plasticity and actively exacerbates broad cognitive decline, entirely independently of any overt, structural myelin degradation.⁴³ This complex dynamic powerfully underscores the central thesis of this work: autophagic failure in any highly specialized glial subpopulation inevitably escapes the boundaries of that cell, cascading systemically into profound, irreversible neuronal dysfunction and network collapse.

Chapter 3: Subcellular Vulnerabilities: Neuronal

Terminals and the Endoplasmic Reticulum

To fully, comprehensively comprehend the vast landscape of autophagic failure within the central nervous system, the pathological analysis must shift its focus from broad cell types to the highly specialized, geographically isolated subcellular domains that exhibit unique, structural vulnerabilities to proteostatic stress: specifically, the extreme distal synaptic terminals of neurons, and the highly dynamic, complex reticular network of the endoplasmic reticulum (ER). 3.1 The Tyranny of Distance: Presynaptic Autophagy As previously established, neurons pose a unique, almost insurmountable geographical and logistical challenge for standard cellular proteostasis. Presynaptic terminals, the primary sites of neurotransmitter release, can be located centimeters or even, in humans, meters away from the cellular soma, placing them incredibly far from the primary, centralized sites of lysosomal biogenesis and heavy protein synthesis.³ To survive the intense metabolic stress of continuous firing, these isolated synapses rely almost entirely on the rapid, highly localized induction of autophagic vesicle formation. This presynaptic autophagy is not constitutively active at high levels; rather, it is dynamically and precisely regulated by immediate neuronal activity and local calcium influx.¹⁴ Specific proteins, such as Endophilin-A (EndoA), act as critical molecular sensors at the synapse. Upon the influx of calcium during periods of high synaptic activity, EndoA undergoes essential conformational flexibility—specifically mediated by the highly conserved residue D265—which promotes the drastic curving of local synaptic membranes.¹⁴ Concurrently, kinases such as LRRK2 phosphorylate EndoA at the specific S75 site, further modifying the membrane architecture to allow for the physical docking of critical autophagic initiation factors like Atg3, thereby initiating rapid autophagosome formation locally, directly at the synaptic bouton.¹⁴ This highly localized process is exquisitely selective, acting specifically to clear damaged synaptic vesicle (SV) proteins—which are rapidly degraded by the high reactive oxygen species (ROS) environment inherent to neurotransmission—usually executing clearance within a remarkably brief 5 to 10-minute window.¹⁴ Furthermore, presynaptic scaffolding proteins such as Bassoon act as crucial negative regulators, actively inhibiting E3 ubiquitin ligases like Parkin to prevent the runaway, hyperactive autophagic consumption of the entire healthy synaptic vesicle pool.¹⁴ When this exquisitely tuned, localized system fails due to genetic mutation, or is physically interrupted by the sheer volume of pathological proteins, the synapse collapses. For instance, when the toxic overexpression of α-synuclein occurs, the resulting aggregates physically and sterically block the narrow axonal transport corridors, preventing the necessary trafficking of autophagic vesicles back toward somatic lysosomes.⁴⁶ Furthermore, α-synuclein physically disrupts the vital transport of the transmembrane protein Atg9 from the ER to the Golgi apparatus, effectively shutting down the biogenesis of new autophagosomes.⁴⁶ Denied its localized clearance mechanism, the synapse rapidly becomes choked with damaged vesicles, oxidized lipids, and misfolded proteins.⁴⁶ This localized, distal synaptic failure invariably precedes actual somatic cell death by significant margins, manifesting clinically as the very early, subtle cognitive and motor deficits seen in the prodromal phases of AD and PD, long before widespread neurodegeneration is detectable via gross neuroimaging.²¹ 3.2 ER-Phagy and the Failure of Subdomain Remodeling The Endoplasmic Reticulum (ER) is a massive, highly dynamic tubular-reticular organelle network responsible for absolutely critical cellular functions, including precise intracellular calcium homeostasis, complex lipid synthesis, and the physical synthesis, folding, and maturation of over one-third of the entire cellular proteome.⁴⁷ Because of its vast, shifting surface area and the requirement for continuous morphological restructuring to meet changing cellular demands, the ER must undergo its own highly specialized, distinct form of selective autophagy, formally termed "ER-phagy" or reticulophagy.⁴⁸ ER-phagy is strictly governed by a distinct suite of ER-resident transmembrane receptor proteins that possess highly specific LC3-interaction regions (LIRs) or GABARAP-interaction motifs (GIMs), allowing them to directly recruit expanding autophagosomal membranes to the ER surface.⁴⁹ Crucially, the deployment of these receptors is highly subdomain specific,

reflecting the diverse architecture of the organelle itself. FAM134B (RETREG1) and SEC62 are

primarily responsible for the degradation, regulation, and spatial remodeling of broad ER

sheets, whereas the dynamin-related GTPase ATL3 (Atlastin 3) and the reticulon protein RTN3L

preferentially and selectively target the highly curved ER tubules.⁴⁹ The profound vulnerability of the highly specialized ER-phagy system is violently and unequivocally illustrated by severe human genetic disorders. Pathological mutations in the specific genes encoding either the FAM134B receptor or the ATL3 receptor are known to cause Hereditary Sensory and Autonomic Neuropathy (HSAN), a devastating, crippling monogenic neurodegenerative disease.⁴⁹ The molecular failure mechanism in these cases is exquisitely specific: a structural inability to bind LC3/GABARAP proteins, or a failure in the reticulon homology domains (RHDs) to induce necessary membrane curvature, prevents the physical fragmentation and subsequent lysosomal engulfment of the ER membrane.⁴⁹ In the specific case of FAM134B depletion, the neuronal cell completely loses the ability to dynamically remodel its ER sheets. This forces the neuron into a state of chronic, unresolved ER stress, culminating in a catastrophic, hypersensitive response to further metabolic insults and the rapid, widespread apoptosis of long-projecting sensory and autonomic neurons.⁴⁹

ER-Phagy Targeted ER Primary Pathological Primary

Receptor Subdomain Autophagic Consequence Disease

Function of Association

Mutation/Failu re

FAM134B ER Sheets ER membrane Inability to HSAN; fragmentation remodel Exacerbated via RHD sheets; Parkinson's extreme ER stress sensitivity

ATL3 ER Tubules Dynamin-relat Defective HSAN

ed membrane COPII vesicle tethering formation; trafficking collapse

SEC62 ER Sheets / Recovery from Accumulation Neurodegener

General acute ER stress of misfolded ation / luminal Malignancy proteins

RTN3L ER Tubules Membrane Loss of tubular Age-related

curvature network Cognitive induction turnover impairment Furthermore, the failure of specific ER-phagy pathways is deeply, causally implicated in the progression of Parkinson's disease. In the pathogenesis of PD, the aberrant accumulation of toxic α-synuclein occurs specifically within the ER lumen, triggering immense, chronic ER stress and the gross physical expansion of the ER network as the cell desperately attempts to manage the unfolded protein load.²⁸ In healthy, physiological states, FAM134B-mediated ER-phagy would rapidly attenuate this severe dysfunction by selectively excising and delivering the bloated, toxic ER domains to the lysosome for safe degradation. However, detailed postmortem transcriptomic and proteomic analyses of the substantia nigra in human PD patients reveal a marked, pathological, and highly specific decrease in the levels of FAM134B and CCPG1 ER-phagy receptors.²⁸ The resultant, cascading failure to successfully execute ER-phagy strips the vulnerable dopaminergic neuron of its primary defense mechanism against structural ER overload, leaving it entirely defenseless against the relentless, progressive proteotoxicity induced by α-synuclein aggregation.²⁸

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.

Conclusion

The extensive historiographical, molecular, and in vivo biological evidence synthesized and presented in this doctoral thesis demands a profound, foundational restructuring of our conceptual and clinical approach to the etiology of neurodegenerative disease. The complex pathogenesis of devastating, untreatable disorders such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis can no longer be accurately or effectively modeled as a simple, linear trajectory of neuron-autonomous proteostatic failure. Rather, the evidence overwhelmingly indicates that neurodegeneration is the terminal, visible manifestation of a massive, systemic collapse in the highly integrated, interdependent glial-neuronal autophagic network. Astrocytes stand firmly at the absolute center of this transcellular network. Their unique ability to dynamically upregulate LC3B-mediated and SQSTM1-dependent autophagic flux serves as the brain's primary, frontline defense against the runaway accumulation of extracellular amyloid pathology.²⁷ More profoundly, their execution of transmitophagy—the active, targeted consumption and lysosomal degradation of damaged, evulsed neuronal mitochondria—highlights an extraordinary level of transcellular biological reliance previously undocumented in classical neuroscience.²⁵ When these robust astrocytic lysosomes eventually fail, either through genetic lesion or the burden of chronological aging, highly vulnerable projection neurons are literally crushed under the accumulating metabolic weight of their own toxic, aging organelles.²⁵ Simultaneously, the broader glial consortium collapses in parallel. Microglia, overwhelmed by the sheer volume of aggregates, shift disastrously from vigilant, neuroprotective phagocytes to paralyzed, SASP-secreting agents of chronic neuroinflammation, actively accelerating the demise of the neurons they are meant to protect.⁵ Concurrently, senescent oligodendrocytes, failing to maintain adequate autophagic turnover of myelin proteins, physically disrupt myelin integrity and actively poison the local synaptic environment via toxic chemokine signaling.⁴³ Within the fragile neuron itself, the severe spatial constraints dictating localized presynaptic autophagy, combined with highly specific receptor deficits at the endoplasmic reticulum (e.g., the loss of FAM134B-mediated ER-phagy), guarantee that when critical glial support inevitably withdraws, the neuron will swiftly and permanently succumb to overwhelming proteotoxic stress.¹⁴

Future Directions and Therapeutic Implications

Recognizing neurodegeneration fundamentally as a systemic, glia-centric failure of metabolic clearance opens several highly specific, previously overlooked therapeutic vectors that possess the potential to alter the clinical landscape of these diseases:

1. Targeted Glial Autophagic Induction: Standard, non-specific pharmacological mTOR inhibitors (such as rapamycin) have historically shown extremely limited, highly variable, and often non-specific efficacy in the CNS, frequently failing to stimulate relevant autophagic pathways in target neurons.⁵¹ Future precision pharmacology must focus on developing compounds that specifically and potently upregulate autophagic flux within targeted astrocytic populations (e.g., pharmacologically enhancing LC3B transcriptional plasticity) and microglial subsets, aiming to fully restore their critical phagocytic capacity without simultaneously hyperactivating adjacent neuronal networks.¹⁷
2. Advanced Senotherapeutics: The aggressive, targeted application of advanced senolytics (designed to selectively induce targeted apoptosis specifically in senescent, SASP-producing microglia and exhausted OPCs) and senomorphics (designed to effectively suppress the release of toxic SASP factors without killing the host cell) represents a crucial, highly viable strategy to disrupt and halt the chronic neuroinflammatory feedback loop well before irreversible, widespread neuronal death occurs.⁸
3. Receptor-Specific ER-Phagy Rescues: Next-generation gene therapies and small-molecule interventions specifically targeting the functional restoration, stabilization, or forced upregulation of uniquely vulnerable ER-phagy receptors, most notably FAM134B and ATL3, hold immense, unprecedented therapeutic potential for diseases characterized by prominent, early-stage ER stress and devastating luminal α-synuclein aggregation.²⁸ In conclusion, the central nervous system is only as resilient as its underlying, transcellular clearance mechanisms. By fundamentally shifting the scientific and clinical gaze away from the terminal pathology of the dying neuron and toward the progressive, insidious failure of the surrounding glial network, researchers can unearth the true, systemic origins of neurodegeneration. This vital paradigm shift moves the scientific field significantly closer to realizing viable interventions that can ultimately preserve the mind by repairing, supporting, and maintaining its essential metabolic foundation.

Works cited

1. Henn RE, Noureldein MH, Elzinga SE, Kim B, Savelieff MG, Feldman EL. Glial-neuron crosstalk in health and disease: A focus on metabolism, obesity, and cognitive impairment. Neurobiol Dis 2022;170:105766. DOI 10.1016/j.nbd.2022.105766.

2. Lee JH, Chang W, Min SS, Song DY, Yoo HI. Beyond Support Cells: Astrocytic Autophagy as a Central Regulator of CNS Homeostasis and Neurodegenerative Diseases. Cells 2025;14(17). DOI 10.3390/cells14171342.

3. Jimenez-Sanchez M, Pampliega O, Soukup SF. Editorial: Autophagy in the central nervous system: Focus on neurons, glia and neuron-glia interactions. Front Cell Dev Biol 2022;10:1036587. DOI 10.3389/fcell.2022.1036587.

4. Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol 2024;25(11):926-946. DOI 10.1038/s41580-024-00757-5.

5. Potential targets of microglia in the treatment of neurodegenerative..., accessed

Zhao W, Liu Z, Wu J, Liu A, Yan J. Potential targets of microglia in the treatment of neurodegenerative diseases: Mechanism and therapeutic implications. Neural Regen Res 2026;21(4):1497-1511. DOI 10.4103/NRR.NRR-D-24-01343.

6. Freisem D, Hoenigsperger H, Catanese A, Sparrer KMJ. Inborn errors of canonical autophagy in neurodegenerative diseases. Hum Mol Genet 2025;34(R1):R23-R34. DOI 10.1093/hmg/ddae179.

7. Sloan SA, Barres BA. Glia as primary drivers of neuropathology in TDP-43 proteinopathies. Proceedings of the National Academy of Sciences 2013;110(12):4439-4440. DOI 10.1073/pnas.1301608110.

8. Hayashide LS, Pessoa B, Dias G, Pontes B, Pinto RS, Diniz LP. From Neuron-Centric to Glia-Centric: How Aging Glial Networks Drive Neurodegenerative Disease. J Neurochem 2026;170(1):e70361. DOI 10.1111/jnc.70361.

9. Hayashide LS, Pessoa B, Dias G, Pontes B, Pinto RS, Diniz LP. From Neuron-Centric to Glia-Centric: How Aging Glial Networks Drive Neurodegenerative Disease. J Neurochem 2026;170(1):e70361. DOI 10.1111/jnc.70361.

10. Strohm L, Behrends C. Glia-specific autophagy dysfunction in ALS. Semin Cell Dev Biol 2020;99:172-182. DOI 10.1016/j.semcdb.2019.05.024.

11. Ahremenko E, Andreev A, Apushkin D, Korkotian E. Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets. Int J Mol Sci 2025;26(24). DOI 10.3390/ijms262411995.

12. Nixon RA, Yang DS. Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol 2012;4(10). DOI 10.1101/cshperspect.a008839.

13. Komatsu M, Kominami E, Tanaka K. Autophagy and Neurodegeneration. Autophagy 2006;2(4):315-317. DOI 10.4161/auto.2974.

14. Smith EM, Coughlan ML, Maday S. Turning garbage into gold: Autophagy in synaptic function. Curr Opin Neurobiol 2025;90:102937. DOI 10.1016/j.conb.2024.102937.

15. Targeting autophagy in astrocytes: a potential for neurodegenerative disease intervention, accessed February 19, 2026, https://www.frontiersin.org/journals/cellular-neuroscience/articles/ 025.1584767/full

16. Potokar M, Jorgačevski J. Targeting autophagy in astrocytes: a potential for neurodegenerative disease intervention. Front Cell Neurosci 2025;19:1584767.025.1584767.

    Find this paper

17. New brain cell cleaner: astrocytes raise possibility of Alzheimer's disease treatment, accessed February 19, 2026, https://www.eurekalert.org/news-releases/1058725

18. From Then 'till Now: The History of Autophagy and Cancer Research - Novus Biologicals, accessed February 19, 2026, https://www.novusbio.com/antibody-news/antibodies/from-then-till-now-the-his tory-of-autophagy-and-cancer-research

19. Autophagy - Wikipedia, accessed February 19, 2026, https://en.wikipedia.org/wiki/Autophagy

20. Ohsumi Y. Historical landmarks of autophagy research. Cell Res 2014;24(1):9-23. DOI 10.1038/cr.2013.169.

21. Ralph A. Nixon, MD, PhD laboratory | Center for Dementia Research, accessed February 19, 2026, https://www.cdr.rfmh.org/research/nixon-lab/

22. Lai AY, Dhami KS, Todd KG. Moving past the "neuroncentric" perspective: a role for glia in neuropsychiatric disorders. J Psychiatry Neurosci 2009;34(3):173-4. PMID 19448845.

23. Hayashide LdS, Pessoa B, Dias G, Pontes B, Pinto RS, Diniz LP. From Neuron‐Centric to Glia‐Centric: How Aging Glial Networks Drive Neurodegenerative Disease. Journal of Neurochemistry 2026;170(1). DOI 10.1111/jnc.70361.

24. Transcellular mitophagy - National Center for Microscopy and Imaging Research - University of California San Diego, accessed February 19, 2026, https://camera.crbs.ucsd.edu/research/highlights/2014_MarshArmstrong.shtm

25. Davis CO, Kim K, Bushong EA, Mills EA, Boassa D, Shih T, et al.. Transcellular degradation of axonal mitochondria. Proceedings of the National Academy of Sciences 2014;111(26):9633-9638. DOI 10.1073/pnas.1404651111.

26. García-Domínguez M. Interplay Between Aging and Glial Cell Dysfunction: Implications for CNS Health. Life (Basel) 2025;15(10). DOI 10.3390/life15101498.

27. Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al.. Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer's disease. Mol Neurodegener 2024;19(1):55. DOI 10.1186/s13024-024-00740-w.

28. Kim DY, Shin JY, Lee JE, Kim HN, Chung SJ, Yoo HS, et al.. A selective ER-phagy exerts neuroprotective effects via modulation of α-synuclein clearance in parkinsonian models. Proc Natl Acad Sci U S A 2023;120(37):e2221929120. DOI 10.1073/pnas.2221929120.

29. Di Malta C, Fryer JD, Settembre C, Ballabio A. Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder. Proc Natl Acad Sci U S A 2012;109(35):E2334-42. DOI 10.1073/pnas.1209577109.

30. Bai I, Keyser C, Zhang Z, Rosolia B, Hwang JY, Zukin RS, et al.. Epigenetic regulation of autophagy in neuroinflammation and synaptic plasticity. Front Immunol 2024;15:1322842. DOI 10.3389/fimmu.2024.1322842.

31. Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al.. Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer's disease. Mol Neurodegener 2024;19(1):55. DOI 10.1186/s13024-024-00740-w.

32. Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al.. Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer's disease. Mol Neurodegener 2024;19(1):55. DOI 10.1186/s13024-024-00740-w.

33. Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al.. Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer's disease. Mol Neurodegener 2024;19(1):55. DOI 10.1186/s13024-024-00740-w.

34. Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al.. Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer's disease. Mol Neurodegener 2024;19(1):55. DOI 10.1186/s13024-024-00740-w.

35. Davis CH, Marsh-Armstrong N. Discovery and implications of transcellular mitophagy. Autophagy 2014;10(12):2383-4. DOI 10.4161/15548627.2014.981920.

36. NFE2L1 as a central regulator of proteostasis in neurodegenerative diseases: interplay with autophagy, ferroptosis, and the proteasome - Frontiers, accessed February 19, 2026, https://www.frontiersin.org/journals/molecular-neuroscience/articles/ ol.2025.1551571/full

37. di Malta C, Fryer J, Settembre C, Andrea B. Astrocyte dysfunction triggers neurodegeneration in a lysosomal storage disorder. Molecular Genetics and Metabolism 2013;108(2):S35. DOI 10.1016/j.ymgme.2012.11.070.

https://pmc.ncbi.nlm.nih.gov/articles/PMC3435187/

38. Lu J, Di Florio DN, Boya P, Maday S, Springer W, Chu CT. Autophagy and mitophagy at the synapse and beyond: implications for learning, memory and neurological disorders. Autophagy 2025;22(1):10-52. DOI 10.1080/15548627.2025.2581217.

39. Sheeler C, Rosa JG, Ferro A, McAdams B, Borgenheimer E, Cvetanovic M. Glia in Neurodegeneration: The Housekeeper, the Defender and the Perpetrator. Int J Mol Sci 2020;21(23). DOI 10.3390/ijms21239188.

40. The importance of non-canonical autophagy pathways in Alzheimer’s disease pathology and potential therapies. Research Features 2022. DOI 10.26904/rf-141-2616504317.

41. Jülg J, Strohm L, Behrends C. Canonical and Noncanonical Autophagy Pathways in Microglia. Mol Cell Biol 2021;41(3):e0038920. DOI 10.1128/MCB.00389-20.

42. Toader C, Tataru CP, Munteanu O, Serban M, Covache-Busuioc RA, Ciurea AV, et al.. Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS. Int J Mol Sci 2024;25(23). DOI 10.3390/ijms252312613.

43. Autophagy in Oligodendrocyte Lineage Cells Controls..., accessed February 19, 2026, https://www.researchgate.net/publication/384076980_Autophagy_in_Oligodendr ocyte_Lineage_Cells_Controls_Oligodendrocyte_Numbers_and_Myelin_Integrity_i n_an_Age-dependent_Manner

44. Ettle B, Schlachetzki JCM, Winkler J. Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?. Mol Neurobiol 2016;53(5):3046-3062. DOI 10.1007/s12035-015-9205-3.

45. Fleming A, Rubinsztein DC. Autophagy in Neuronal Development and Plasticity. Trends Neurosci 2020;43(10):767-779.2020.07.003.

    Find this paper

46. Cai Q, Ganesan D. Regulation of neuronal autophagy and the implications in neurodegenerative diseases. Neurobiol Dis 2022;162:105582. DOI 10.1016/j.nbd.2021.105582.

47. Shi M, Chai Y, Zhang J, Chen X. Endoplasmic Reticulum Stress-Associated Neuronal Death and Innate Immune Response in Neurological Diseases. Front Immunol 2021;12:794580. DOI 10.3389/fimmu.2021.794580.

48. Why Cells Need To Eat Themselves To Avoid Neurodegenerative Disease, accessed February 19, 2026, https://www.technologynetworks.com/cell-science/news/why-cells-need-to-eatthemselves-to-avoid-neurodegenerative-disease-373974

49. Hübner CA, Dikic I. ER-phagy and human diseases. Cell Death Differ 2020;27(3):833-842. DOI 10.1038/s41418-019-0444-0.

50. ER-phagy Receptor's Intrinsically Disordered Modules Drive ER Fragmentation and ER-phagy | bioRxiv, accessed February 19, 2026, DOI 10.1101/2024.06.18.599470">https://www.biorxiv.org/content/10.1101/2024.06.18.599470

51. Tsvetkov AS, Finkbeiner S. Reply to Rubinsztein and Nixon: Potent and reliable autophagy induction in neurons. Proceedings of the National Academy of Sciences 2010;107(49). DOI 10.1073/pnas.1014950107.